Answers are grounded in this paper and cite their sources.
Accelerated approval pathways have transformed patient access to medicines for serious and lifethreatening conditions over three decades, enabling marketing authorization based on surrogate or intermediate clinical endpoints reasonably predicted to correlate with clinical benefit before confirmatory evidence is available. The social contract underlying this regulatory innovation requires timely and rigorous post-market confirmatory evidence generation in exchange for conditional early access, creating a system whose long-term legitimacy depends on the reliability of both its evidentiary basis and its post-market governance mechanisms. Despite extensive guidance from the Food and Drug Administration, the European Medicines Agency, and the World Health Organization, no validated quantitative decision model exists to systematically weigh the competing factors bearing on pathway designation appropriateness in a manner that is transparent, reproducible, and auditable across review teams and regulatory jurisdictions worldwide. This paper presents the Risk-Based Accelerated Approval Decision Model (RBAADM), a six-dimension composite scoring framework integrating disease severity and condition burden, unmet medical need, evidence quality and surrogate validity, benefit-risk profile, postmarket commitment enforceability, and regulatory system capacity into a 120-point composite index with three clearly defined pathway designation tiers: Standard Approval (0-39), Expedited Approval (40-69), and Accelerated Approval (70-120). The RBAA-DM's theoretical architecture applies the proportionality principle, under which evidence thresholds for marketing authorization should be proportionate to the balance between patient access urgency and regulatory governance capacity to manage residual uncertainty through conditional post-market mechanisms. The model was calibrated using 187 FDA and EMA regulatory decisions from 2010 to 2023. Retrospective validation against independent expert panel assessments achieved 79.1 percent overall concordance, improving to 82.7 percent following behavioral anchor revision based on systematic discordance analysis. The RBAA-DM draws on cardiovascular disease risk quantification from sub-Saharan African clinical populations, composite risk scoring methodology from fraud detection and cybersecurity regulatory compliance, industrial safety governance and environmental risk management maturity frameworks, lifecycle performance assessment evidence, digital governance and algorithmic accountability design, and healthcare policy governance. Integration into pre-submission consultation, internal regulatory review documentation, and international harmonization discussions is recommended as the priority implementation pathway for advancing pharmaceutical regulatory science globally.
No takes yet. Share an insight, caveat, or question.
Felix Ikechukwu Eze (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: